Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Entospletinib · GS-9973

Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Gilead Sciences

Phase 2/3 Most advanced trial
1 Registered trials

What is Entospletinib?

Entospletinib is an orally available inhibitor of spleen tyrosine kinase (Syk). It inhibits Syk activity to suppress B-cell receptor signaling, reducing tumor cell activation, migration, adhesion and proliferation. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
GS-9973
Drug type
Small molecule
Targets
spleen tyrosine kinase (SYK)
Mechanism
Inhibitor of spleen tyrosine kinase (SYK)
Pathways
B-cell receptor signaling
Therapy area
Hematology, Oncology
Developer
Gilead Sciences
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
6I3O3W6O3B

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.